Takeda says its new oral multiple myeloma drug Ninlaro is on course to become its biggest-ever cancer product.

Daiichi Sankyo licenses two abuse-deterrent painkillers from Inspirion to further its pain-management ambitions.

The PD-1 inhibitor patent battle raging between Merck and Bristol-Myers Squibb in the U.S., Europe and Australia has now reached Japan.

Another disciple of Valeant and its price-hiking credo is bidding farewell to its CEO.

AstraZeneca has licensed diabetes drugs Byetta and Bydureon to 3SBio to kickstart sales growth in China.

Piramal added to its run of healthcare acquisitions with a $175 million deal to buy five injectable pain drugs from Johnson & Johnson.

Kyowa Hakko Kirin is rolling out the psoriasis med brodalumab this week in Japan, its first world market, but it faces a tough road ahead.

India's FMRAI union is calling for a mass strike by pharma sales reps in November as protests over working practices gather strength.

Sales and Marketing